Development of IMU-838, an orally available and selective small molecule inhibitor for the treatment of chronic inflammatory and autoimmune diseases
IMU-838 is an orally available small molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH). It is currently in placebocontrolled phase 2 clinical testing in patients suffering from ulcerative colitis. Further…

